Study Condition(s): Mild Cognitive Impairment

A Study of Solanezumab (LY2062430) in Participants With Prodromal Alzheimer's Disease

Study Alias: LZBE

Study Identifier(s): Tool Tip Icon {{ defaultRegistry.registryAnchorText }} NCT02760602 {{ currentLocaleObject.registryAnchorText }}

Terminated Terminated

Study Purpose

The main purpose of this study is to investigate the safety and efficacy of the study drug solanezumab in participants with prodromal Alzheimer's Disease (AD).

Terminated Study

This trial stopped recruiting or enrolling participants prematurely and will not start again. We are no longer examining or treating participants. The trial may have been stopped for many reasons. You may contact Lilly for further information.

Who Participated? Tool Tip Icon

Here you can find out a bit more about the requirements for volunteers who took part in this study


Male Female


55 years
85 years

Time Commitment

Your participation could last up to 28 months and include 29 visits to the study center.
  • Participant must have cognitive impairment that is evaluated as prodromal Alzheimer's disease (AD) by the study investigator

  • Participant must not have had an MRI or CT of brain within the previous 2 years that would be inconsistent with a diagnosis of AD

  • Participant must not have received treatment with a stable dose of an achetylcholinesterase (AChEI) inhibitor or memantine for less than 4 months before entering the study

Where This Study Took Place Tool Tip Icon

193 locations participated
Invalid Postal Code.
Please re-enter postal code.

{{sites.getPageStartCount()}} - {{sites.getPageEndCount()}} of {{sites.totalCount}} Results

0 of {{sites.totalCount}} Results

Distance Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
Closest Location
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}
Other Location(s)
{{site.getDistance() | number:0}} {{convertUnit("imperial", "mile") | translate}} {{convertUnit("imperial", "miles") | translate}}

To improve your experience on Lilly TrialGuide, please use the latest version of Chrome, Firefox, Safari, or Internet Explorer, with Java Script enabled.
This website is not optimized for your browser, as configured.